Enterobacteriaceae Infection Drug Market 2027 by Type, Distribution Channel and Geography | The Insight Partners

Enterobacteriaceae Infection Drug Market Forecast to 2027 - Covid-19 Impact and Global Analysis - By Type (Beta-Lactams Drugs, Carbapenems Drugs, Fluoroquinolones Drugs, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00008464 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Enterobacteriaceae are a large family of different types of germs (bacteria) that commonly cause infections in healthcare settings. Examples of germs in the Enterobacteriaceae family include Escherichia coli (E. coli) and Klebsiella pneumoniae.

MARKET DYNAMICS

Rising prevalence of Enterobacteriaceae infectious diseases, For instance, in 2017, CRE caused an estimated 13,100 infections in hospitalized patients, and 1,100 estimated deaths in the United States increasing modes of spread of the infectious disease and a lack of cleanliness are the driving factors. However, the major factor which will restrain the market growth rapid resistance to drugs currently available for enterobacter infections. Furthermore, launch of new antibiotics with activity against carbapenem-resistant Enterobacteriaceae (CRE) will offer lucrative opportunities in the market.

MARKET SCOPE

`
The "Global Enterobacteriaceae Infection Drug Market analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Enterobacteriaceae Infection Drug Market with detailed market segmentation by type, distribution channel, and geography. The Global Enterobacteriaceae Infection Drug Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Enterobacteriaceae Infection Drug Market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Global Enterobacteriaceae Infection Drug Market is segmented on the basis of type and distribution channel. On the basis of type, market can be classified as beta-lactams drugs, carbapenems drugs, fluoroquinolones drugs, others. On the basis of distribution channel the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies
. ?


REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Enterobacteriaceae Infection Drug Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Enterobacteriaceae Infection Drug Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Enterobacteriaceae Infection Drug Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Enterobacteriaceae Infection Drug Market in these regions.




Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Enterobacteriaceae Infection Drug Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Enterobacteriaceae Infection Drug Market are anticipated to lucrative growth opportunities in the future with the rising demand for Enterobacteriaceae Infection Drug Market in the global market. Below mentioned is the list of few companies engaged in the Enterobacteriaceae Infection Drug Market.

The report also includes the profiles of key Enterobacteriaceae Infection Drug Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Genentech, Inc.
- Allergan
- Novartis AG
- Pfizer Inc.
- Nymox Pharmaceutical Corporation
- Sequoia Sciences, Inc.
- Phico Therapeutics Ltd.
- Melinta Therapeutics, Inc.
- Spero Therapeutics
- Cipla USA, Inc.

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Enterobacteriaceae Infection Drug - By Type
1.3.2 Enterobacteriaceae Infection Drug - By Distribution Channel
1.3.3 Enterobacteriaceae Infection Drug - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ENTEROBACTERIACEAE INFECTION DRUG LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ENTEROBACTERIACEAE INFECTION DRUG - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ENTEROBACTERIACEAE INFECTION DRUG - GLOBAL MARKET ANALYSIS
6.1. ENTEROBACTERIACEAE INFECTION DRUG - GLOBAL MARKET OVERVIEW
6.2. ENTEROBACTERIACEAE INFECTION DRUG - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ENTEROBACTERIACEAE INFECTION DRUG - REVENUE AND FORECASTS TO 2027 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. BETA-LACTAMS DRUGS
7.3.1. Overview
7.3.2. Beta-Lactams Drugs Market Forecast and Analysis
7.4. CARBAPENEMS DRUGS
7.4.1. Overview
7.4.2. Carbapenems Drugs Market Forecast and Analysis
7.5. FLUOROQUINOLONES DRUGS
7.5.1. Overview
7.5.2. Fluoroquinolones Drugs Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. ENTEROBACTERIACEAE INFECTION DRUG - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. ENTEROBACTERIACEAE INFECTION DRUG REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Enterobacteriaceae Infection Drug Overview
9.1.2 North America Enterobacteriaceae Infection Drug Forecasts and Analysis
9.1.3 North America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.1.4 North America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.1.5 North America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.1.5.1 United States Enterobacteriaceae Infection Drug
9.1.5.1.1 United States Enterobacteriaceae Infection Drug by Type
9.1.5.1.2 United States Enterobacteriaceae Infection Drug by Distribution Channel
9.1.5.2 Canada Enterobacteriaceae Infection Drug
9.1.5.2.1 Canada Enterobacteriaceae Infection Drug by Type
9.1.5.2.2 Canada Enterobacteriaceae Infection Drug by Distribution Channel
9.2. EUROPE
9.2.1 Europe Enterobacteriaceae Infection Drug Overview
9.2.2 Europe Enterobacteriaceae Infection Drug Forecasts and Analysis
9.2.3 Europe Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.2.4 Europe Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.2.5.1 Germany Enterobacteriaceae Infection Drug
9.2.5.1.1 Germany Enterobacteriaceae Infection Drug by Type
9.2.5.1.2 Germany Enterobacteriaceae Infection Drug by Distribution Channel
9.2.5.2 France Enterobacteriaceae Infection Drug
9.2.5.2.1 France Enterobacteriaceae Infection Drug by Type
9.2.5.2.2 France Enterobacteriaceae Infection Drug by Distribution Channel
9.2.5.3 Italy Enterobacteriaceae Infection Drug
9.2.5.3.1 Italy Enterobacteriaceae Infection Drug by Type
9.2.5.3.2 Italy Enterobacteriaceae Infection Drug by Distribution Channel
9.2.5.4 Spain Enterobacteriaceae Infection Drug
9.2.5.4.1 Spain Enterobacteriaceae Infection Drug by Type
9.2.5.4.2 Spain Enterobacteriaceae Infection Drug by Distribution Channel
9.2.5.5 United Kingdom Enterobacteriaceae Infection Drug
9.2.5.5.1 United Kingdom Enterobacteriaceae Infection Drug by Type
9.2.5.5.2 United Kingdom Enterobacteriaceae Infection Drug by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Enterobacteriaceae Infection Drug Overview
9.3.2 Asia-Pacific Enterobacteriaceae Infection Drug Forecasts and Analysis
9.3.3 Asia-Pacific Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.3.5.1 Australia Enterobacteriaceae Infection Drug
9.3.5.1.1 Australia Enterobacteriaceae Infection Drug by Type
9.3.5.1.2 Australia Enterobacteriaceae Infection Drug by Distribution Channel
9.3.5.2 China Enterobacteriaceae Infection Drug
9.3.5.2.1 China Enterobacteriaceae Infection Drug by Type
9.3.5.2.2 China Enterobacteriaceae Infection Drug by Distribution Channel
9.3.5.3 India Enterobacteriaceae Infection Drug
9.3.5.3.1 India Enterobacteriaceae Infection Drug by Type
9.3.5.3.2 India Enterobacteriaceae Infection Drug by Distribution Channel
9.3.5.4 Japan Enterobacteriaceae Infection Drug
9.3.5.4.1 Japan Enterobacteriaceae Infection Drug by Type
9.3.5.4.2 Japan Enterobacteriaceae Infection Drug by Distribution Channel
9.3.5.5 South Korea Enterobacteriaceae Infection Drug
9.3.5.5.1 South Korea Enterobacteriaceae Infection Drug by Type
9.3.5.5.2 South Korea Enterobacteriaceae Infection Drug by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Enterobacteriaceae Infection Drug Overview
9.4.2 Middle East and Africa Enterobacteriaceae Infection Drug Forecasts and Analysis
9.4.3 Middle East and Africa Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.4.5.1 South Africa Enterobacteriaceae Infection Drug
9.4.5.1.1 South Africa Enterobacteriaceae Infection Drug by Type
9.4.5.1.2 South Africa Enterobacteriaceae Infection Drug by Distribution Channel
9.4.5.2 Saudi Arabia Enterobacteriaceae Infection Drug
9.4.5.2.1 Saudi Arabia Enterobacteriaceae Infection Drug by Type
9.4.5.2.2 Saudi Arabia Enterobacteriaceae Infection Drug by Distribution Channel
9.4.5.3 U.A.E Enterobacteriaceae Infection Drug
9.4.5.3.1 U.A.E Enterobacteriaceae Infection Drug by Type
9.4.5.3.2 U.A.E Enterobacteriaceae Infection Drug by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Enterobacteriaceae Infection Drug Overview
9.5.2 South and Central America Enterobacteriaceae Infection Drug Forecasts and Analysis
9.5.3 South and Central America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.5.4 South and Central America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.5.5.1 Brazil Enterobacteriaceae Infection Drug
9.5.5.1.1 Brazil Enterobacteriaceae Infection Drug by Type
9.5.5.1.2 Brazil Enterobacteriaceae Infection Drug by Distribution Channel
9.5.5.2 Argentina Enterobacteriaceae Infection Drug
9.5.5.2.1 Argentina Enterobacteriaceae Infection Drug by Type
9.5.5.2.2 Argentina Enterobacteriaceae Infection Drug by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ENTEROBACTERIACEAE INFECTION DRUG, KEY COMPANY PROFILES
11.1. GENENTECH, INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ALLERGAN
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. NOVARTIS AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. NYMOX PHARMACEUTICAL CORPORATION
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SEQUOIA SCIENCES, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. PHICO THERAPEUTICS LTD.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. MELINTA THERAPEUTICS, INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SPERO THERAPEUTICS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. CIPLA USA, INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Genentech, Inc.
2. Allergan
3. Novartis AG
4. Pfizer Inc.
5. Nymox Pharmaceutical Corporation
6. Sequoia Sciences, Inc.
7. Phico Therapeutics Ltd.
8. Melinta Therapeutics, Inc.
9. Spero Therapeutics
10. Cipla USA, Inc.

TIPRE00008464
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking